文献速递垂体与肾上腺疾病

垂体神经内分泌肿瘤复发风险:一项采用五级分类的前瞻性研究

Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

这项前瞻性单中心研究纳入2007至2012年接受垂体神经内分泌肿瘤手术的全部患者,用基于磁共振侵袭、免疫细胞化学、Ki-67、核分裂指数和p53的五级分类对肿瘤分级。365例中1a级占51.2%、2a级32.3%、2b级8.8%、1b级7.7%;213例有随访者中42%在3.5年时复发或进展,分级是无进展生存的显著预测因素(P<0.001)。

要点

  • 五级分类可预测垂体神经内分泌肿瘤术后行为(P<0.001)。
  • 2b级肿瘤复发或进展风险为1a级的3.72倍。
  • 分级、年龄和肿瘤类型为独立预测因素。

核心结论

  • 数据提示将垂体神经内分泌肿瘤分为五级对预测术后肿瘤行为具有预后价值,并能识别早期复发或进展高风险患者。
  • 该分类可使临床医生调整治疗策略并在未来临床试验中对患者进行分层。

研究设计与样本

  • 前瞻性研究,纳入2007至2012年在一家单中心接受垂体神经内分泌肿瘤手术的全部患者。
  • 采用基于磁共振成像侵袭、免疫细胞化学特征、Ki-67、核分裂指数和p53阳性的分级系统对肿瘤分类。
  • 用Kaplan-Meier法计算分级肿瘤的无进展生存率,用log-rank检验比较,并用Cox回归模型进行多因素分析。

主要发现

  • 365例患者中1a级51.2%、2a级32.3%、2b级8.8%、1b级7.7%。
  • 213例有随访的患者中,42%在3.5年时复发(n=52)或进展(n=37)。
  • 分级是无进展生存的显著预测因素(P<0.001)。
  • 多因素分析显示分级(P<0.001)、年龄(P=0.035)和肿瘤类型(P=0.028)是复发和/或进展的独立预测因素。
  • 2b级肿瘤的复发或进展风险为1a级肿瘤的3.72倍。

临床怎么用

  • 作者认为五级分类对预测术后肿瘤行为具有预后价值,可识别早期复发或进展高风险患者,使临床医生得以调整治疗策略并在未来临床试验中对患者分层。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most pituitary neuroendocrine tumors (PitNETs) show benign behavior, but a substantial number are invasive, recur, or resist medical treatment. Based on a retrospective case-control study, we recently proposed a classification of PitNETs of prognostic relevance. This prospective study aims to test the value of this classification in an independent patient cohort. METHODS: All patients who underwent PitNET surgery from 2007 to 2012 in one single center were included. Using a grading system based on invasion on magnetic resonance imaging, immunocytochemical profile, Ki-67, mitotic index, and p53 positivity, tumors were classified. Progression-free survival of the graded tumors was calculated by the Kaplan-Meier method and compared using the log-rank test. A multivariate analysis, using a Cox regression model, was also performed. RESULTS: In total, 365 patients had grade 1a PitNETs (51.2%), followed by grade 2a (32.3%), 2b (8.8%), and 1b tumors (7.7%). Of 213 patients with a follow-up, 42% had recurrent (n = 52) or progressive disease (n = 37) at 3.5 years. Grade was a significant predictor of progression-free survival (P < 0.001). Multivariate analysis indicated grade (P < 0.001), age (P = 0.035), and tumor type (P = 0.028) as independent predictors of recurrence and/progression. This risk was 3.72-fold higher for a grade 2b tumor compared with grade 1a tumor. CONCLUSIONS: Our data suggest that classification of PitNETs into five grades is of prognostic value to predict postoperative tumor behavior and identifies patients who have a high risk of early recurrence or progression. It therefore will allow clinicians to adapt their therapeutic strategies and stratify patients in future clinical trials.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Raverot G, Dantony E, Beauvy J, et al. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017. PMID: 28651368. doi:10.1210/jc.2017-00773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。